Status:
COMPLETED
The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer
Lead Sponsor:
Yonsei University
Conditions:
Gastric Adenoma
Early Gastric Cancer
Eligibility:
All Genders
19-79 years
Phase:
NA
Brief Summary
Endoscopic submucosal dissection (ESD) is an advanced technique that enables en bloc resection of superficial tumors in the gastrointestinal tract. ESD, however, is a time-consuming procedure that req...
Eligibility Criteria
Inclusion
- Age, between 19 and 79
- Patients with gastric adenoma or early gastric cancer
- Patients with ECOG-PS 0 or 1
- Patients with adequate renal function
- Patients with adequate hepatic function
- Patients with adequate bone marrow function
Exclusion
- Patients who has taken the medications for ulcer including PPIs, H2 blockers, and mucosal protective agents within 3 months prior to the ESD.
- Patients who has taken steroid or NSAIDswithin 3 months prior to the ESD.
- Patients who has undergone gastrostomy
- Patients with allergy for pantoprazole, polaprezinc, or rebamipide.
- Pregnant or breast feeding.
Key Trial Info
Start Date :
January 14 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2016
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT02243618
Start Date
January 14 2015
End Date
April 14 2016
Last Update
March 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sevrance hospital
Seoul, South Korea, 120-752